MENS NASDAQ
Jyong Biotech Ltd. Ordinary Shares
1W: +7.4%
1M: -3.1%
3M: -0.9%
YTD: -36.1%
1Y: -95.5%
$2.18
+0.15 (+7.39%)
Weekly Expected Move ±12.4%
$2
$2
$2
$2
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$165.7M
52W Range1.43-63
Volume29,712
Avg Volume76,299
Beta2.24
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOFu-Feng Kuo
Employees27
SectorHealthcare
IndustryBiotechnology
IPO Date2025-06-17
Websitejyongbio.com/
23Fâ3, No.â¯95, Section 1, Xintai 5th Road
New Taipei City, TP 221
TW
New Taipei City, TP 221
TW
886 2 2732 5205
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orchestrated through various subsidiary entities, including Health Ever Bio-Tech and Genvace. The company is actively advancing a robust pipeline of drug candidates, which notably features MCS-2, currently undergoing Phase III trials for benign prostatic hyperplasia (BPH); PCP, which is in Phase II development for prostate cancer; and IC, presently in pre-clinical stages.
Latest News
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Jyong Biotech Responds to Share Price and Volume Movement
Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry
Recent Insider Trades
No insider trades found